INFORMAZIONI SU
MILAN Noemi
 |
Supervisore: Dr.ssa Cecchin
|
| Neoadjuvant chemoradiotherapy (nCRT) including capecitabine, followed by total mesorectal excision has become the standard of care for patients with locally advanced rectal cancer (LARC), with variable response rate and risks to develop severe toxicities. Tumor pharmacogenomics pattern, including somatic mutations, copy number variations (CNVs) and RNA expression profiling have been hypothesised to affect therapy outcomes and help in the personalization of treatment. The aim of this project is to identify predictive and prognostic pharmacogenomic markers capable of helping clinicians in LARC patients’ selection for personalized nCRT treatment. To achieve this objective, DNA will be isolated from pre-treatment blood samples and matched tumor tissue biopsies previously collected from about 140 LARC patients treated at IRCCS CRO Aviano between July 2011 and December 2020. |
|